The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
The forefront of ovarian cancer therapy: update on PARP inhibitors
Open accessAbstract
BACKGROUND In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm. DESIGN We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. We discuss the efficacy and safety of these agents in the all-comer and biomarker-selected populations studied in clinical trials, and compare the strengths and limitations of the various trial designs. We also consider priorities for future research, with a particular focus on patient selection and future regimens for populations with high unmet need. RESULTS Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. Differences in trial design (treatment and/or maintenance setting; single-agent or combination; bevacizumab or no bevacizumab), patient selection (surgical outcome, biomarker eligibility, prognosis) and primary analysis population (intention-to-treat, BRCA mutated or homologous recombination deficiency positive) affect the conclusions that can be drawn from these trials. Overall survival data are pending and there is limited experience regarding long-term safety. CONCLUSIONS PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Self-citationNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
Self-citationA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Self-citationOlaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Self-citationPujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Self-citationColeman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Self-citationOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Self-citationSwisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Self-citationVeliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913
Self-citationKatsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30029-4 · Cited by 533
Self-citationMechanisms of PARP inhibitor sensitivity and resistance
D’Andrea, A. D. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.08.021 · Cited by 489
Exploring and comparing adverse events between PARP inhibitors
LaFargue, C. J., Dal Molin, G. Z., Sood, A. K., & Coleman, R. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30786-1 · Cited by 487
Self-citationPARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Noordermeer, S. M., & van Attikum, H. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.008 · Cited by 456
Lin, K. K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 432
Self-citationPignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Self-citationWeekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
Biomarkers for Homologous Recombination Deficiency in Cancer
Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy085 · Cited by 329
Detecting the mutational signature of homologous recombination deficiency in clinical samples
Gulhan, D. C., Lee, J. J.-K., Melloni, G. E. M., Cortés-Ciriano, I., & Park, P. J. (2019) · Nature Genetics · doi:10.1038/s41588-019-0390-2 · Cited by 314
Kim, H., George, E., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 291
Mirza, M. R., Åvall Lundqvist, E., Birrer, M. J., dePont Christensen, R., Nyvang, G.-B., Malander, S., Anttila, M., Werner, T. L., Lund, B., Lindahl, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30515-7 · Cited by 242
Self-citationCandidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, D. R., Dougherty, B. A., Lai, Z., Fielding, A., Grinsted, L., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0274-8 · Cited by 233
Norquist, B. M., Brady, M. F., Harrell, M. I., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Burger, R. A., Tewari, K. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1327 · Cited by 230
Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J.-W., O'Donnell, D. M., Hook, J., Coyle, C., Blagden, S., Brenton, J. D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32259-7 · Cited by 209
Safety and dose modification for patients receiving niraparib
Berek, J. S., Matulonis, U. A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy181 · Cited by 189
Self-citationLiu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz018 · Cited by 185
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 177
Karam, A., Ledermann, J. A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B.-H., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx011 · Cited by 153
Frey, M. K., & Pothuri, B. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0039-8 · Cited by 151
Haynes, B. M., Murai, J., & Lee, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.003 · Cited by 144
SEOM clinical guidelines in Hereditary Breast and ovarian cancer
On behalf of the SEOM Hereditary Cancer Working Group, Llort, G., Chirivella, I., Morales, R., Serrano, R., Sánchez, A. B., Teulé, À., Lastra, E., Brunet, J., Balmañà, J., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1435-3 · Cited by 135
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
Mirza, M. R., Pignata, S., & Ledermann, J. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy174 · Cited by 134
Self-citationStronach, E. A., Paul, J., Timms, K. M., Hughes, E., Brown, K. L., Neff, C. D., Perry, M., Gutin, A., El-Bahrawy, M. A., Steel, J. H., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0034 · Cited by 125
Kraus, C. S., Hoyer, J., Vasileiou, G., Wunderle, M., Lux, M. P., Fasching, P. A., Krumbiegel, M., Uebe, S., Reuter, M. S., Beckmann, M. W., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30428 · Cited by 121
Tumiati, M., Hietanen, S., Hynninen, J., Pietilä, E. A., Färkkilä, A., Kaipio, K., Roering, P., Huhtinen, K., Alkodsi, A., Li, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3770 · Cited by 117
Póti, Á., Gyergyák, H., Németh, E., Rusz, O., Tóth, S., Kovácsházi, C., Chen, D., Szikriszt, B., Spisák, S., Takeda, S., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1867-0 · Cited by 116
Rouzier, R., Gouy, S., Selle, F., Lambaudie, É., Floquet, A., Fourchotte, V., Pomel, C., Colombo, P., Kalbacher, E., Martin-Françoise, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.036 · Cited by 108
Cecere, S. C., Giannone, G., Salutari, V., Arenare, L., Lorusso, D., Ronzino, G., Lauria, R., Cormio, G., Carella, C., Scollo, P., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.023 · Cited by 108
Self-citationMechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
Francica, P., & Rottenberg, S. (2018) · Genome Medicine · doi:10.1186/s13073-018-0612-8 · Cited by 105
Pignata, S., Lorusso, D., Joly, F., Gallo, C., Colombo, N., Sessa, C., Bamias, A., Pisano, C., Selle, F., Zaccarelli, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5506 · Cited by 74
Self-citationPellegrino, B., Mateo, J., Serra, V., & Balmañà, J. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000480 · Cited by 74
González-Martı́n, A., Oza, A. M., Embleton-Thirsk, A., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Bertrand, M. A., Beale, P. J., Cervantes, A. M. R., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.08.036 · Cited by 63
Self-citationPujade-Lauraine, É., Fujiwara, K., Ledermann, J. A., Oza, A. M., Kristeleit, R. S., Ray-Coquard, I., Richardson, G. E., Sessa, C., Yonemori, K., Banerjee, S. N., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.04.053 · Cited by 63
Self-citationVeneris, J. T., Matulonis, U. A., Liu, J. F., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.021 · Cited by 63
Front-line therapy of advanced ovarian cancer: new approaches
Ledermann, J. A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx452 · Cited by 56
García, Y. G., Ferré, A. D. J., Mendiola, C., Barretina-Ginesta, M.-P., Gaba, L., Santaballa, A., Bover, I., Gil-Martín, M., Manzano, A., Pérez, M. J. R., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000256 · Cited by 56
Self-citationLedermann, J. A., Colombo, N., Oza, A. M., Fujiwara, K., Birrer, M. J., Randall, L. M., Poddubskaya, E. V., Scambia, G., Shparyk, Y. V., Lim, M.-C., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.025 · Cited by 56
Self-citationMechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
Mweempwa, A., & Wilson, M. K. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.50 · Cited by 48
Burgess, B. T., Anderson, A. M., McCorkle, J. R., Wu, J., Ueland, F. R., & Kolesar, J. (2020) · Diagnostics · doi:10.3390/diagnostics10020121 · Cited by 47
Possik, P. A., Müller, J., Gerlach, C., Kenski, J. C. N., Huang, X., Shahrabi, A., Krijgsman, O., Song, J., Smit, M. A., Gerritsen, B., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.024 · Cited by 43
Telli, M. L., Metzger, O., Timms, K. M., Evans, B. A., Vogel, D., Wei, H., Jones, J. T., WENSTRUP, R. J., McKee, M. D., Sullivan, D. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.519 · Cited by 35
Matsumoto, K., Nishimura, M., Onoe, T., Sakai, H., Urakawa, Y., Onda, T., & Yaegashi, N. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz090 · Cited by 35
Cited by
Valabrega, G., Scotto, G., Tuninetti, V., Pani, A., & Scaglione, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084203 · Cited by 93
Yang, X., Wu, G., Yang, F., He, L., Xie, X., Li, L., Yang, L., Ma, Y., Zhang, Q., Chen, J., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5574130 · Cited by 25
Metadata
- Authors
- Mirza, M. R., Coleman, R. L., González-Martín, A., Moore, K. N., Colombo, N., Ray-Coquard, I., & Pignata, S.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 31
- Issue
- 9
- Pages
- 1148-1159
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3036364440
- Cited by
- 365
- References
- 56
- FWCI
- 18.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.